PROM1 and endometrial cancer: To extend these findings, we assessed whether there was evidence of differential methylation of CpG sites in the CD133 promoter in three sets of benign and malignant tissue samples derived from women who either had no evidence of endometrial cancer or had been diagnosed with endometrial cancer.